683 related articles for article (PubMed ID: 32326335)
21. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
Taghiloo S; Norozi S; Asgarian-Omran H
Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
[TBL] [Abstract][Full Text] [Related]
22. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.
Kharas MG; Okabe R; Ganis JJ; Gozo M; Khandan T; Paktinat M; Gilliland DG; Gritsman K
Blood; 2010 Feb; 115(7):1406-15. PubMed ID: 20008787
[TBL] [Abstract][Full Text] [Related]
23. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Reikvam H; Tamburini J; Skrede S; Holdhus R; Poulain L; Ersvaer E; Hatfield KJ; Bruserud Ø
Br J Haematol; 2014 Jan; 164(2):200-11. PubMed ID: 24383842
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
25. Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1.
Sun X; Yang S; Song W
Biomed Pharmacother; 2020 Apr; 124():109731. PubMed ID: 31954876
[TBL] [Abstract][Full Text] [Related]
26. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
27. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway.
Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T
FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634
[TBL] [Abstract][Full Text] [Related]
28.
Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
[No Abstract] [Full Text] [Related]
29. Effects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathway.
Li LJ; Chai Y; Guo XJ; Chu SL; Zhang LS
Mol Med Rep; 2018 Jun; 17(6):7886-7892. PubMed ID: 29620275
[TBL] [Abstract][Full Text] [Related]
30. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells.
Bertacchini J; Frasson C; Chiarini F; D'Avella D; Accordi B; Anselmi L; Barozzi P; Forghieri F; Luppi M; Martelli AM; Basso G; Najmaldin S; Khosravi A; Rahim F; Marmiroli S
Adv Biol Regul; 2018 May; 68():2-9. PubMed ID: 29576448
[TBL] [Abstract][Full Text] [Related]
32. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.
Mise J; Dembitz V; Banfic H; Visnjic D
Pathol Oncol Res; 2011 Sep; 17(3):645-56. PubMed ID: 21336564
[TBL] [Abstract][Full Text] [Related]
33. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
34. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
Stengel S; Petrie KR; Sbirkov Y; Stanko C; Ghazvini Zadegan F; Gil V; Skopek R; Kamiński P; Szymański Ł; Brioli A; Zelent A; Schenk T
Br J Haematol; 2022 Jul; 198(2):338-348. PubMed ID: 35468223
[TBL] [Abstract][Full Text] [Related]
35. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
Lee JE; Lim MS; Park JH; Park CH; Koh HC
Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260
[TBL] [Abstract][Full Text] [Related]
36. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
Su Y; Li X; Ma J; Zhao J; Liu S; Wang G; Edwards H; Taub JW; Lin H; Ge Y
Biochem Pharmacol; 2018 Feb; 148():13-26. PubMed ID: 29208365
[TBL] [Abstract][Full Text] [Related]
37. Long non‑coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells.
Yang Y; Dai W; Sun Y; Zhao Z
Oncol Rep; 2019 Apr; 41(4):2311-2320. PubMed ID: 30720129
[TBL] [Abstract][Full Text] [Related]
38. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
39. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
[TBL] [Abstract][Full Text] [Related]
40. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
